A composition for promoting the secretion of glucagon-like peptide-1, and its preparation method and application

Abstract

The present invention provides a composition for promoting the secretion of glucagon-like peptide-1, its preparation method, and application, relating to the technical fields of food and health food. The composition comprises polygonatum powder, ampelopsis glauca leaf powder, tagatose, fig powder, and Ilex paraguariensis leaf extract. The composition for promoting the secretion of glucagon-like peptide-1 of the present invention can effectively promote the secretion of GLP-1, lower blood sugar, and maintain healthy blood sugar levels.

Description

Technical Field

[0001] The present invention relates to the technical field of food and health food, and in particular to a composition for promoting the secretion of glucagon-like peptide-1, a preparation method and an application thereof. Background Art

[0002] Diabetes is a hereditary disease caused by endocrine disorders. Clinically, it can be broadly divided into two types, with Type 2 diabetes accounting for over 90% of patients. Type 2 diabetes is not insulin-dependent and often presents with symptoms of decreased insulin efficacy, leading to abnormal sugar, fat, and protein metabolism.

[0003] Glucagon-like peptide-1 (GLP-1), secreted by enteroendocrine L cells, is a pleiotropic hormone. GLP-1 not only protects pancreatic islet cells and improves insulin resistance, but also exerts various mechanistic effects, such as delayed gastric emptying, reduced food absorption, and lipid metabolism regulation. It has the potential to benefit pancreatic islet function, diet control, glucose homeostasis, inflammation relief, and cardiovascular protection. The goal of promoting endogenous GLP-1 expression and secretion to develop antidiabetic drugs has garnered widespread attention, with current research focusing on the regulatory effects of various drugs on endogenous GLP-1 secretion. However, long-term use of traditional Western medications for diabetes, such as GLP-1 receptor agonists, GLP-1 inactivator inhibitors, and GLP-1 analogs, can result in various side effects, including liver and kidney damage and insulin resistance.

[0004] Literature: Xie, Song-ZiYang, GuangJiang, Xian-MinQin, Dan-YangLi, Qiang-MingZha, Xue-QiangPan, Li-HuaJin, Chuan-ShanLuo, Jian-Ping.Polygonatumcyrtonema HuaPolysaccharide Promotes GLP-1Secretion from Enteroendocrine L-Cells throughSweet Taste Receptor-Mediated cAMP Signaling[J].Journal of Agricultural and Food Chemistry,2020,68(25):6864-6872. It is reported that Polygonatum cyrtonema polysaccharide can promote the secretion of GLP-1 from enteroendocrine L-Cells through sweet taste receptor-mediated cAMP signaling and lower blood sugar. Chinese invention patent CN106074753A discloses a traditional Chinese medicine complex for promoting the secretion of glucagon-like peptide-1 and its preparation method. The main ingredients of the traditional Chinese medicine complex, measured by weight, include 1-3 parts of Scutellaria baicalensis, 2-5 parts of Pueraria lobata, and 2-5 parts of Coptis chinensis. The traditional Chinese medicine complex in this invention promotes the synthesis of intestinal L cells and thus promotes the secretion of GLP-1 by activating the bitter receptors of intestinal L cells and their downstream pathways.

[0005] While some traditional Chinese medicines can lower blood sugar, their raw materials are complex, with different active ingredients found in different parts of the herb, and different extraction methods can also yield different active ingredients. Existing drugs reported in the art are only moderately effective in promoting GLP-1 secretion, and require high dosages. Therefore, there is an urgent need to develop new products that promote GLP-1 secretion. Summary of the Invention

[0006] In response to the problems existing in the prior art, the present invention provides a composition for promoting the secretion of glucagon-like peptide-1, a preparation method thereof, and an application thereof. The composition for promoting the secretion of glucagon-like peptide-1 provided by the present invention has synergistic effects among its components, has a high promoting effect on GLP-1 secretion, and is effective in inhibiting the rise in postprandial blood sugar.

[0007] To achieve the above object, the technical solution adopted by the present invention is as follows:

[0008] The invention provides a composition for promoting the secretion of glucagon-like peptide-1, comprising polygonatum sibiricum powder, ampelopsis glauca leaf powder, tagatose, fig powder and ilex paraguariensis leaf extract (also known as ilex paraguariensis leaf (mate tea leaf) extract).

[0009] Furthermore, the composition comprises, by weight, 0.3-8 parts of polygonatum powder, 0.5-1 parts of ampelopsis leaf powder, 0.1-7 parts of tagatose, 0.1-0.5 parts of fig powder and 0.1-13.7 parts of yerba mate leaf (mate tea) extract.

[0010] Preferably, the composition comprises, by weight, 0.3-0.5 parts of polygonatum powder, 0.8-1 parts of ampelopsis leaf powder, 0.1-0.3 parts of tagatose, 0.1-0.2 parts of fig powder and 13-13.7 parts of yerba mate leaf (mate tea) extract.

[0011] Further preferably, the composition comprises, by weight, 0.3 parts of polygonatum powder, 0.8 parts of ampelopsis leaf powder, 0.1 parts of tagatose, 0.1 parts of fig powder and 13.7 parts of yerba mate leaf (mate tea) extract.

[0012] Furthermore, the weight ratio of the Ampelopsis grossedentata leaf powder, the fig powder and the Ilex paraguariensis leaf (yerba mate tea) extract is 0.8:0.1:13.7.

[0013] Furthermore, the weight ratio of the polygonatum powder, ampelopsis grossedentata leaf powder and ilex paraguariensis leaf (yerba mate tea) extract is 0.3:0.8:13.7.

[0014] Furthermore, the preparation method of the polygonatum powder comprises the following steps: adding polygonatum slices into water, extracting, separating, concentrating, and drying to obtain the polygonatum powder.

[0015] Furthermore, the present invention also provides a method for preparing the above-mentioned composition, comprising the following steps: mixing polygonatum powder, ampelopsis glauca leaf powder, tagatose, fig powder and ilex paraguariensis leaf (mate tea) extract to obtain the composition.

[0016] Furthermore, the above-mentioned composition provided by the present invention or the composition prepared by the above-mentioned preparation method can be used to prepare food, health food or medicine that helps maintain healthy blood sugar levels.

[0017] Furthermore, the present invention also provides a product that helps maintain healthy blood sugar levels, including the above-mentioned composition or the composition prepared by the above-mentioned preparation method.

[0018] Furthermore, the product also includes auxiliary materials that can be added in the fields of food, health food or medicine.

[0019] Furthermore, the auxiliary materials include one or more of thickeners, emulsifiers, preservatives, colorants, adhesives, fillers and lubricants.

[0020] Furthermore, the dosage form of the product includes granules, liquids, capsules, tablets, pastes, powders or pills.

[0021] The technical effects achieved by the present invention are:

[0022] The composition for promoting the secretion of glucagon-like peptide-1 of the present invention uses selected raw materials such as polygonatum powder, ampelopsis glauca leaf powder, tagatose, fig powder and Ilex paraguariensis leaf (yerba mate tea) extract. Through the scientific compounding and synergistic enhancement of the raw materials, it can effectively promote the secretion of GLP-1, lower blood sugar, and maintain a healthy blood sugar level, contributing new ideas for the preparation of drugs for treating diabetes. DETAILED DESCRIPTION

[0023] The following describes the embodiments of the present invention through specific examples. Those skilled in the art will readily understand the other advantages and benefits of the present invention from the disclosure herein. The present invention may also be implemented or applied through various other specific embodiments, and the details in this specification may be modified or altered based on different viewpoints and applications without departing from the spirit of the present invention.

[0024] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing specific embodiments rather than for limiting the scope of protection of the present invention.

[0025] When numerical ranges are given in the examples, it should be understood that, unless otherwise specified herein, both endpoints of each numerical range and any value between the two endpoints may be selected. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the present invention belongs.

[0026] It is worth noting that the Polygonatum sibiricum tablets used in the present invention were purchased from Bozhou Jinyitang Pharmaceutical Co., Ltd.; Ampelopsis grossedentata leaf powder was purchased from Shaanxi Jiuyuan Biotechnology Co., Ltd.; tagatose, CAS: 87-81-0, with an active substance content of 99%, was purchased from Shandong Jinan Yuncheng Biotechnology Co., Ltd.; fig powder was purchased from Euromed, SA; and Ilex paraguariensis leaf (yerba mate tea) extract was purchased from Triunfo do Brasi1 Ind.eCom Ltda. The remaining raw materials are all common commercially available products, and therefore their sources are not specifically limited.

[0027] Example 1

[0028] A composition for promoting the secretion of glucagon-like peptide-1, comprising, by weight, 0.3 parts of polygonatum sibiricum powder, 0.8 parts of ampelopsis serrulata leaf powder, 0.1 parts of tagatose, 0.1 parts of fig powder and 13.7 parts of yerba mate leaf (mate tea) extract.

[0029] The preparation method of the above composition specifically comprises the following steps: mixing polygonatum powder, ampelopsis glauca leaf powder, tagatose, fig powder and ilex paraguariensis leaf (mate tea) extract to obtain the composition.

[0030] The preparation method of polygonatum powder is specifically as follows:

[0031] S1. Add the Polygonatum sibiricum tablets to ultrapure water 15 times the weight of the Polygonatum sibiricum tablets, soak for 30 minutes, stir and heat to 75°C for extraction for 1.5 hours, collect the first extraction mixture, centrifuge at a speed of 5000r for 20 minutes to obtain the first extraction supernatant and residue;

[0032] S2. Add 15 times the weight of ultrapure water to the residue in step S1, perform a second extraction according to step S1, collect the second extraction mixture, centrifuge at a speed of 5000r, centrifuge for 20min, and collect the second extraction supernatant;

[0033] S3. Combine the supernatants from the two extractions in steps S1 and S2, concentrate to 1 / 5 of the original volume using a rotary evaporator, and freeze-dry in vacuo for 48 hours to obtain polygonatum powder.

[0034] Example 2

[0035] A composition for promoting the secretion of glucagon-like peptide-1, comprising, by weight, 0.3 parts of polygonatum sibiricum powder, 0.5 parts of ampelopsis serrulata leaf powder, 0.1 parts of tagatose, 0.1 parts of fig powder and 0.1 parts of yerba mate leaf (mate tea) extract.

[0036] The preparation method of the above composition specifically comprises the following steps: mixing polygonatum powder, ampelopsis glauca leaf powder, tagatose, fig powder and ilex paraguariensis leaf (mate tea) extract to obtain the composition.

[0037] The preparation method of Polygonatum sibiricum powder is the same as that in Example 1.

[0038] Example 3

[0039] A composition for promoting the secretion of glucagon-like peptide-1, comprising, by weight, 8 parts of polygonatum sibiricum powder, 1 part of ampelopsis serrulata leaf powder, 7 parts of tagatose, 0.5 part of fig powder and 13.7 parts of yerba mate leaf (mate tea) extract.

[0040] The preparation method of the above composition specifically comprises the following steps: mixing polygonatum powder, ampelopsis glauca leaf powder, tagatose, fig powder and ilex paraguariensis leaf (mate tea) extract to obtain the composition.

[0041] The preparation method of Polygonatum sibiricum powder is the same as that in Example 1.

[0042] Example 4

[0043] A composition for promoting the secretion of glucagon-like peptide-1, comprising, by weight, 0.5 parts of polygonatum sibiricum powder, 0.1 parts of ampelopsis serrulata leaf powder, 0.3 parts of tagatose, 0.2 parts of fig powder, and 13 parts of yerba mate leaf (mate tea) extract.

[0044] The preparation method of the above composition specifically comprises the following steps: mixing polygonatum powder, ampelopsis glauca leaf powder, tagatose, fig powder and ilex paraguariensis leaf (mate tea) extract to obtain the composition.

[0045] The preparation method of Polygonatum sibiricum powder is the same as that in Example 1.

[0046] Comparative Example 1

[0047] The only difference from Example 1 is that the Ampelopsis grossedentata leaf powder and the Fig powder are replaced with an equal amount of Ilex paraguariensis leaf (Mate tea leaf) extract in the composition.

[0048] That is, the composition comprises, by weight, 0.3 parts of polygonatum powder, 0.1 parts of tagatose and 14.6 parts of yerba mate leaf (mate tea) extract.

[0049] The preparation method of the above composition specifically comprises the following steps: mixing polygonatum powder, tagatose and yerba mate leaf extract to obtain the composition.

[0050] The preparation method of Polygonatum sibiricum powder is the same as that in Example 1.

[0051] Comparative Example 2

[0052] The only difference from Example 1 is that the extract of Ilex paraguariensis leaves (Mate tea leaves) and fig powder are replaced with an equal amount of Ampelopsis grossedentata leaf powder in the composition.

[0053] That is, the composition comprises, by weight, 0.3 parts of polygonatum sibiricum powder, 14.6 parts of ampelopsis glauca leaf powder and 0.1 parts of tagatose.

[0054] The preparation method of the above composition specifically comprises the following steps: mixing polygonatum powder, ampelopsis glauca leaf powder and tagatose to obtain the composition.

[0055] The preparation method of Polygonatum sibiricum powder is the same as that in Example 1.

[0056] Comparative Example 3

[0057] The only difference from Example 1 is that the Ampelopsis grossedentata leaf powder and Ilex paraguariensis leaf (Mate tea leaf) extract in the composition are replaced with an equal amount of fig powder.

[0058] That is, the composition comprises, by weight, 0.3 parts of polygonatum sibiricum powder, 0.1 parts of tagatose, and 14.6 parts of fig powder.

[0059] The preparation method of the above composition specifically comprises the following steps: mixing polygonatum powder, tagatose and fig powder to obtain the composition.

[0060] The preparation method of Polygonatum sibiricum powder is the same as that in Example 1.

[0061] Comparative Example 4

[0062] The only difference from Example 1 is that the content of each raw material in the composition is different.

[0063] That is, the composition comprises, by weight, 5 parts of polygonatum powder, 0.5 parts of ampelopsis leaf powder, 10 parts of tagatose, 0.5 parts of fig powder and 0.05 parts of yerba mate leaf (mate tea) extract.

[0064] The preparation method of the above composition specifically comprises the following steps: mixing polygonatum powder, ampelopsis glauca leaf powder, tagatose, fig powder and ilex paraguariensis leaf (mate tea) extract to obtain the composition.

[0065] The preparation method of Polygonatum sibiricum powder is the same as that in Example 1.

[0066] Comparative Example 5

[0067] The only difference from Example 1 is that the content of each raw material in the composition is different.

[0068] That is, the composition comprises, by weight, 3 parts of polygonatum powder, 0.3 parts of ampelopsis leaf powder, 3 parts of tagatose, 0.03 parts of fig powder and 15 parts of yerba mate leaf (mate tea) extract.

[0069] The preparation method of the above composition specifically comprises the following steps: mixing polygonatum powder, ampelopsis glauca leaf powder, tagatose, fig powder and ilex paraguariensis leaf (mate tea) extract to obtain the composition.

[0070] The preparation method of Polygonatum sibiricum powder is the same as that in Example 1.

[0071] 1. Cell Assay: Glucagon-like Peptide-1 Content Determination (Mouse Small Intestinal Endocrine Cells STC-1)

[0072] 1. Test samples: The compositions of each group in the Examples and Comparative Examples were prepared into sample solutions using deionized water (wherein, the cytotoxicity tests of Comparative Examples 4 and 5 were not tested at lower concentrations).

[0073] Detection kit: F2027-A mouse glucagon-like peptide 1 (GLP-1) ELISA scientific research kit 96T (brand: Fankewei), purchased from Shanghai Kexing Trading Co., Ltd.; the enzyme-labeled reagents, coating plates, washing solutions, color developers, standards, standard diluents, sealing films, stop solutions, and sealing bags used in the test process of the present invention were all taken from the above-mentioned kit.

[0074] Negative control group (cells without drug): deionized water;

[0075] 2. Test method:

[0076] (1) On the first day, the logarithmic growth phase mouse small intestinal endocrine cells STC-1 were digested and prepared to a density of 7.0×10 4 pc / mL were inoculated into 24-well plates, 1 mL per well;

[0077] (2) The next day, after the cells have grown into a monolayer, the original culture medium was removed and 400 μL of each sample solution with a cell activity greater than or equal to 80% in the cytotoxicity test and a negative control solution (one group was shared by Example 1-4 and Comparative Example 1-3, and negative control solutions were set separately for Comparative Example 4 and Comparative Example 5), with three replicate wells per group;

[0078] (3) After the sample addition is completed, the 24-well plate is placed in a 37°C, 5% CO2 incubator for 5 hours. After the incubation period, the cell supernatant is collected as the sample to be tested;

[0079] (4) Addition of standard samples: Set up standard sample wells and sample wells, and add 50 μL of standard samples of different concentrations (the standard samples in the detection kit were diluted to concentrations of 10 pg / ml, 20 pg / ml, 40 pg / ml, 80 pg / ml, and 160 pg / ml, respectively) to each standard sample well;

[0080] (5) Sample addition: First add 40 μL of sample diluent to the sample well, then add 10 μL of the sample to be tested; do not add to the blank well; incubate at 37°C for 30 min;

[0081] (6) Liquid preparation: dilute the 30-fold concentrated washing solution with 30-fold distilled water for later use;

[0082] (7) Washing: Remove the sealing film, discard the liquid, spin dry, fill each well with washing solution, let it stand for 30 seconds and then discard, repeat 5 times, and pat dry;

[0083] (8) Add enzyme: Add 50 μL of enzyme-labeled reagent to each well, except for the blank well, and incubate at 37°C for 30 min; wash;

[0084] (9) Color development: Add 50 μL of color developer A to each well, then add 50 μL of color developer B, gently shake to mix, and develop color at 37°C in the dark for 10 minutes;

[0085] (10) Termination: Add 50 μL of stop solution to each well to terminate the reaction (the blue color immediately turns yellow);

[0086] (11) Measurement: Use the blank well as the zero setting and measure the absorbance (OD value) of each well in sequence at a wavelength of 450 nm. The measurement should be performed within 15 minutes after adding the stop solution.

[0087] The GLP-1 concentration of each group was measured, and the GLP-1 upregulation rate and the GLP-1 upregulation amount per unit of raw material within the safe dose were calculated. The GLP-1 upregulation rate = (GLP-1 concentration of each test sample group - GLP-1 concentration of the negative control group) / GLP-1 concentration of the negative control group × 100%. The GLP-1 upregulation amount per unit of raw material within the safe dose = (GLP-1 concentration of each test sample group - GLP-1 concentration of the negative control group) / action concentration. The final results are shown below:

[0088] Table 1 Changes in GLP-1

[0089]

[0090] The results, as shown in Table 1, show that the GLP-1 upregulation rate in each Example group exceeded 13%, and the GLP-1 upregulation per unit of raw material within the safe dose reached a high level. Among them, the formulation corresponding to Example 1 had the most significant in vitro GLP-1-stimulating effect on the relevant derived cells. The GLP-1-stimulating effects of the comparative example groups were significantly worse than those of the Example groups.

[0091] 2. Animal Testing

[0092] 1. Experimental Animals

[0093] One hundred and sixty healthy male Sprague-Dawley rats weighing 200 ± 20 g were enrolled. They were given free access to food and water. The temperature was maintained at 22–25°C, the humidity at 40%–60%, and a strict 12-h light / 12-h dark cycle was followed.

[0094] 2. Grouping and Dosage

[0095] The rats were randomly divided into a blank control group, Example 1-4 groups and Comparative Example 1-5 groups according to their body weight, a total of 10 groups, with 16 rats in each group.

[0096] Administration: Groups 1-4 were gavaged with the composition of Example 1-4, and Groups 1-5 were gavaged with the composition of Comparative Example 1-5, at a dose of 40 mg / kg / day, once a day for 4 consecutive weeks. The blank control group was gavaged with an equal dose of normal saline.

[0097] (1) Effect of the composition that promotes the secretion of glucagon-like peptide-1 on blood glucose

[0098] At the end of the fourth week after oral gavage, the rats were fasted overnight (water was not allowed) (8 rats in each group) and orally administered with glucose solution (2 g / kg body weight). Blood samples were collected at 0 min, 15 min, 30 min, 60 min, 90 min and 120 min after oral administration of glucose, and blood glucose levels were measured using a blood glucose meter.

[0099] Table 2 Changes in blood glucose in rats

[0100]

[0101]

[0102] Note: In the table, * indicates that there is a significant difference compared with the blank control group, P < 0.05; # indicates that there is a significant difference compared with Example 1, P < 0.05.

[0103] The results are shown in Table 2. There is no significant difference in fasting blood sugar between the various examples and comparative groups and the blank control group. However, after gavage with glucose solution, the blood sugar level of the blank control group was significantly higher than that of the various examples and comparative groups within 30 minutes. At 30 minutes, the blood sugar levels of the various examples and comparative groups showed a certain decrease, while the blood sugar level of the blank control group decreased slowly. It can be seen from the blood sugar levels at various time points after oral administration of glucose solution that the blood sugar level of the blank control group was significantly higher than that of the various examples and comparative groups; and the blood sugar levels of the comparative groups were significantly higher than those of the Example 1 group. The results show that after gavage with the composition of each example group, the rats had a better blood sugar-lowering effect.

[0104] (2) Effect of the composition that promotes the secretion of glucagon-like peptide-1 on the secretion of GLP-1

[0105] At the end of the fourth week of gavage, the rats were fasted overnight (8 rats in each group) and injected with glucose solution (2 g / kg body weight) intraperitoneally under anesthesia. Blood was collected from the portal vein at 0 min, 15 min, 30 min, 60 min, 90 min and 120 min after glucose injection, and the secretion of GLP-1 was detected using an enzyme-linked immunosorbent assay (ELISA) kit.

[0106] Table 3 GLP-1 secretion in rats

[0107]

[0108]

[0109] Note: In the table, * indicates that there is a significant difference compared with the blank control group, P < 0.05; # indicates that there is a significant difference compared with Example 1, P < 0.05.

[0110] The results are shown in Table 3. Fifteen minutes after glucose injection, GLP-1 levels were significantly elevated in Example 1-4 and Comparative Example 1-5 groups compared to the blank control group. At each time point after glucose injection, GLP-1 levels in each Example and Comparative Example group were significantly higher than in the blank control group. GLP-1 levels were significantly elevated in the Example 1 group compared to the Comparative Example groups. These results demonstrate that the compositions of the present invention can promote GLP-1 secretion, thereby lowering blood sugar and helping to maintain healthy blood sugar levels.

[0111] In summary, the composition for promoting the secretion of glucagon-like peptide-1 of the present invention is made of selected raw materials such as polygonatum powder, ampelopsis leaf powder, tagatose, fig powder and Ilex paraguariensis leaf (yerba mate tea) extract. Through the scientific compounding of the raw material components and synergistic enhancement, it can promote the secretion of glucagon-like peptide-1, and has the effect of lowering blood sugar and maintaining blood sugar health.

[0112] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A composition for promoting the secretion of glucagon-like peptide-1, characterized in that: The invention comprises, by weight, 0.3-8 parts of polygonatum sibiricum powder, 0.5-1 parts of ampelopsis glauca leaf powder, 0.1-7 parts of tagatose, 0.1-0.5 parts of fig powder and 0.1-13.7 parts of ilex paraguariensis leaf extract; The preparation method of the polygonatum powder comprises the following steps: adding polygonatum slices into water, extracting, separating, concentrating and drying to obtain the polygonatum powder.

2. The composition according to claim 1, wherein: The invention comprises, by weight, 0.3-0.5 parts of polygonatum sibiricum powder, 0.8-1 parts of ampelopsis glauca leaf powder, 0.1-0.3 parts of tagatose, 0.1-0.2 parts of fig powder and 13-13.7 parts of ilex paraguariensis leaf extract.

3. The composition according to claim 1, wherein: The invention comprises, by weight, 0.3 parts of polygonatum sibiricum powder, 0.8 parts of ampelopsis glauca leaf powder, 0.1 parts of tagatose, 0.1 parts of fig powder and 13.7 parts of ilex paraguariensis leaf extract.

4. The composition according to claim 1, wherein: The weight ratio of the Ampelopsis grossedentata leaf powder, fig powder and Ilex paraguariensis leaf extract is 0.8:0.1:13.7; the weight ratio of the Polygonatum sibiricum powder, Ampelopsis grossedentata leaf powder and Ilex paraguariensis leaf extract is 0.3:0.8:13.

7.

5. The method for preparing the composition according to any one of claims 1 to 4, wherein: The method comprises the following steps: mixing polygonatum powder, ampelopsis glauca leaf powder, tagatose, fig powder and ilex paraguariensis leaf extract to obtain the product.

6. Use of the composition according to any one of claims 1 to 4 or the composition prepared by the preparation method according to claim 5 in preparing a food or medicine that helps maintain a healthy blood sugar level.

7. A product that helps maintain healthy blood sugar levels, characterized by: The composition is prepared by the composition according to any one of claims 1 to 4 or the composition prepared by the preparation method according to claim 5.

8. The product according to claim 7, characterized in that: The dosage forms of the product include granules, liquids, capsules, tablets, pastes, powders or pills.

Images